Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2018-09-30 Regulatory Filings
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
ArcticZymes AS secures first supply agreement for utility of Salt Active Nuclease in Gene Therapy
Regulatory Filings Classification · 99% confidence The document is a short press release announcing a specific business event: ArcticZymes AS securing its first supply agreement for its Salt Active Nuclease (SAN) enzyme utility in gene therapy manufacturing. It details the commercial value range (1-3 MNOK per annum) and quotes management. This is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing ownership changes or dividends. It is a specific business development announcement. Since there is no specific category for 'Business Development Announcement' or 'Supply Agreement', and it is a short, specific announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory/corporate news that doesn't fit the highly specific financial report codes. Given the short length and press release format, it is not an announcement *of* a report (RPA), but a standalone news item.
2018-09-30 English
ArcticZymes AS secures first supply agreement for utility of Salt Active Nuclease in Gene Therapy
Regulatory Filings Classification · 100% confidence The document is a press release dated September 30, 2018, announcing that ArcticZymes AS (a subsidiary of Biotec Pharmacon ASA) has secured its first supply agreement for its Salt Active Nuclease (SAN) enzyme to be used in the cGMP manufacturing of viruses for gene therapy. This announcement details a commercial agreement, its potential value (1-3 MNOK per annum), and its strategic importance as a 'milestone.' This type of announcement, focusing on a specific commercial contract or business development, does not fit the definitions for formal regulatory reports (10-K, IR, AR), financial results (ER, MRQ), or shareholder actions (AGM-R, DVA). It is a general business update regarding a significant contract. Since there is no specific category for 'Commercial Contract Announcement' or 'Business Development Update,' and it is not a general regulatory filing (RNS) or a presentation (IP), the most appropriate classification among the provided options is 'Regulatory Filings' (RNS) as a general announcement, or potentially 'Capital/Financing Update' (CAP) if the agreement implied a major shift in funding, which it does not explicitly state. Given the nature of announcing a specific, material commercial deal, and lacking a better fit, RNS serves as the best general regulatory announcement fallback. However, upon reviewing the definitions, this is a specific business development announcement. If we must choose from the list, and it's not a formal financial report, RNS is the catch-all. Let's re-evaluate: It is a news release about a contract. It is not a proxy, dividend, director dealing, or formal financial statement. RNS is the most suitable general regulatory/news announcement category when a specific business development category is missing.
2018-09-30 English
Biotec Pharmacon changes management in the wound care area
Board/Management Information Classification · 99% confidence The document is a press release announcing a change in senior management: Stuart Devine is leaving, and Finn Ketler is hired to manage the wound care area. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management.
2018-09-20 English
Biotec Pharmacon changes management in the wound care area
Board/Management Information Classification · 99% confidence The document explicitly announces a change in senior personnel within the company, stating that Stuart Devine is leaving and Mr. Finn Ketler has been hired to manage the wound care area. This directly corresponds to the definition of Board/Management Information.
2018-09-20 English
Biotec Pharmacon ASA will present at LSX Nordic Conference
Investor Presentation Classification · 98% confidence The document is structured as a presentation, containing slides, bullet points, disclaimers typical of forward-looking statements, and high-level strategic and clinical data summaries (e.g., 'High margin growth business', 'SBG® in Neuroblastoma vaccine trial', 'ArcticZymes Road Map'). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER). The content strongly suggests it is material prepared for investors to explain strategy, pipeline progress, and market opportunities, which aligns perfectly with the definition of an Investor Presentation (IP). The document length (8002 chars) is substantial enough to be the presentation itself, not just an announcement of one.
2018-08-30 English
Biotec Pharmacon ASA will present at LSX Nordic Conference
Report Publication Announcement Classification · 98% confidence The document is very short (498 characters) and announces that Biotec Pharmacon ASA will present at the LSX Nordic Conference today, August 30th, and explicitly states, 'Please find the presentation attached.' This structure—a brief announcement stating that presentation materials are attached or available—fits the definition of a Report Publication Announcement (RPA), as per the 'MENU VS MEAL' rule, rather than the Investor Presentation (IP) itself. It is an announcement about the presentation materials.
2018-08-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.